Brentuximab vedotin治疗12例复发或难治性霍奇金淋巴瘤的临床研究.DOC

·临床研究· Brentuximab vedotin治疗12例复发或难治性霍奇金淋巴瘤的临床研究 曹志刚1, 彭朝津1, 王志红1, 刘 默1, 周宏伟1, 靖 彧2, 杨清明* （1解放军总医院第一附属医院老年肿瘤血液科, 北京 100048; 2解放军总医院血液科, 北京 100853） 【摘 要】目的 观察新型靶向治疗药Brentuximab vedotin治疗复发或难治性霍奇金淋巴瘤的临床疗效和不良反应。方法 选取我院住院治疗的12例复发或难治性霍奇金淋巴瘤患者，经病理及免疫组化证实为CD30抗原阳性的霍奇金淋巴瘤，所有病例均接受过二线或三线方案化疗，化疗中位数13个疗程，7例曾接受自体干细胞移植，其中2例行自体干细胞移植后因复发接受异基因干细胞移植。给药方法：Brentuximab vedotin单药剂量1.2～1.8mg/kg，静脉滴注，每21天给药一次。患者共接受2～16疗程，治疗中位数4个疗程。结果 完全缓解2/12（17%），部分缓解7/12（58%），稳定2/12（17%），进展1/12（8%）。主要不良反应有乏力、白细胞减少、发热、脱发、转氨酶增高、恶心、末梢神经炎、疼痛等，患者均可耐受。结论 Brentuximab vedotin治疗复发或难治性霍奇金淋巴瘤具有良好的临床疗效，不良反应轻微，患者多能耐受。 【关键词】霍奇金病; 治疗; CD30; Brentuximab vedotin 【中图分类号】 R733.4 【文献标识码】 A 【DOI】 ? Clinical study of Brentuximab vedotin in treatment of relapsed or refractory Hodgkin’s lymphoma: report of 12 cases Cao Zhi-Gang1, Peng Chao-Jin1, Wang Zhi-Hong1, Liu Mo1, Zhou Hong-wei1, Jing Yu2, Yang Qing-Ming1* (1Department of Geriatric Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China; 2Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China) 【Abstract】 Objective To determine the efficiency and adverse reaction of the new targeted drug——Brentuximab vedotin, in treatment of patients with relapsed or refractory Hodgkin’s lymphoma. Methods Twelve patients with relapsed or refractory CD30 Aantigen-positive Hodgkin’s lymphoma confirmed by pathology and immunohistochemistry treated in our hospital were enrolled in this study. All patients had received second- or third-line chemotherapy regimens, with median 13.7 cycles of chemotherapy, and 7 of them had been treated with autologous stem cell transplantation, including 2 cases underwent autologous stem cell transplantation then relapsed after allogeneic stem cell transplantation. Brentuximab vedotin was given at a dose of 1.2 to 1.8 mg/kg, via intravenous injection, for a treatment phase of 21 d. Patients received 2 to 16 treatment courses, with a median number of 4 courses. Results Complete rem